{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:12:26Z","timestamp":1791141146830,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171594"],"award-info":[{"award-number":["82171594"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11359-4","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:50:26Z","timestamp":1760611826000},"page":"4285-4299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Virtual screening and experimental validation of small-molecule compounds targeting AR in prostate cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Zhongqiang","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexue","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhunan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congzhe","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-6783","authenticated-orcid":false,"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"31","key":"11359_CR1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403331121","volume":"121","author":"M Pornour","year":"2024","unstructured":"Pornour M, Jeon HY, Ryu H, Khadka S, Xu R, Chen H et al (2024) USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity. Proc Natl Acad Sci U S A 121(31):e2403331121. https:\/\/doi.org\/10.1073\/pnas.2403331121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"11359_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/epi-2023-0374","volume":"16","author":"I Fischetti","year":"2024","unstructured":"Fischetti I, Botti L, Sulsenti R, Cancila V, Enriquez C, Ferri R et al (2024) Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response. Epigenomics 16(9):653\u2013670. https:\/\/doi.org\/10.2217\/epi-2023-0374","journal-title":"Epigenomics"},{"key":"11359_CR3","doi-asserted-by":"publisher","unstructured":"Dai C, Dehm SM, Sharifi N (2023) Targeting the Androgen Signaling Axis in Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(26):4267\u201378. Epub 2023\/07\/10. https:\/\/doi.org\/10.1200\/jco.23.00433. PubMed PMID: 37429011; PubMed Central PMCID: PMCPMC10852396 manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org\/rwc or ascopubs.org\/jco\/authors\/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).","DOI":"10.1200\/jco.23.00433"},{"key":"11359_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/jci170809","author":"C Lafront","year":"2024","unstructured":"Lafront C, Germain L, Campolina-Silva GH, Weidmann C, Berthiaume L, Hovington H et al (2024) The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression. J Clin Invest. https:\/\/doi.org\/10.1172\/jci170809","journal-title":"J Clin Invest"},{"issue":"4","key":"11359_CR5","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022112184","volume":"42","author":"X Li","year":"2023","unstructured":"Li X, Zhuo S, Cho YS, Liu Y, Yang Y, Zhu J et al (2023) YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth. EMBO J 42(4):e112184. https:\/\/doi.org\/10.15252\/embj.2022112184","journal-title":"EMBO J"},{"issue":"6","key":"11359_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/ju.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E et al (2023) Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol 209(6):1082\u20131090. https:\/\/doi.org\/10.1097\/ju.0000000000003452","journal-title":"J Urol"},{"issue":"7","key":"11359_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ccell.2023.05.016","volume":"41","author":"H Wang","year":"2023","unstructured":"Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B et al (2023) Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell 41(7):1345\u201362.e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.05.016","journal-title":"Cancer Cell"},{"issue":"8","key":"11359_CR8","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","volume":"38","author":"ND Shore","year":"2021","unstructured":"Shore ND, Lalibert\u00e9 F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D et al (2021) Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors. Adv Ther 38(8):4520\u20134540. https:\/\/doi.org\/10.1007\/s12325-021-01823-6","journal-title":"Adv Ther"},{"key":"11359_CR9","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.2147\/ijgm.S465031","volume":"17","author":"X Li","year":"2024","unstructured":"Li X, Cui P, Zhao X, Liu Z, Qi Y, Liu B (2024) Development and validation of a clinic machine learning classifier for the prediction of risk stratifications of prostate cancer bone metastasis progression to castration resistance. Int J Gen Med 17:2821\u20132831. https:\/\/doi.org\/10.2147\/ijgm.S465031","journal-title":"Int J Gen Med"},{"key":"11359_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082565","author":"S Smani","year":"2025","unstructured":"Smani S, DuBois J, Ajjawi I, Sohoni N, Choksi AU, Lokeshwar SD et al (2025) Advances in current treatment paradigms for metastatic hormone-sensitive prostate cancer. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14082565","journal-title":"J Clin Med"},{"issue":"1","key":"11359_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S (2022) Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther 7(1):198. https:\/\/doi.org\/10.1038\/s41392-022-01042-7","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"11359_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14737140.2024.2405103","volume":"24","author":"CD Miller","year":"2024","unstructured":"Miller CD, Likasitwatanakul P, Toye E, Hwang JH, Antonarakis ES (2024) Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment. Expert Rev Anticancer Ther 24(11):1085\u20131100. https:\/\/doi.org\/10.1080\/14737140.2024.2405103","journal-title":"Expert Rev Anticancer Ther"},{"key":"11359_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194877","author":"Z Zheng","year":"2022","unstructured":"Zheng Z, Li J, Liu Y, Shi Z, Xuan Z, Yang K et al (2022) The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers14194877","journal-title":"Cancers"},{"key":"11359_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-3-031-11836-4_11","volume":"1390","author":"L Cato","year":"2022","unstructured":"Cato L, Shomali M (2022) AR Structural Variants and Prostate Cancer. Adv Exp Med Biol 1390:195\u2013211. https:\/\/doi.org\/10.1007\/978-3-031-11836-4_11","journal-title":"Adv Exp Med Biol"},{"issue":"19","key":"11359_CR15","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/0008-5472.Can-23-0285","volume":"83","author":"R Sun","year":"2023","unstructured":"Sun R, Yan B, Li H, Ding D, Wang L, Pang J et al (2023) Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. Cancer Res 83(19):3192\u20133204. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-0285","journal-title":"Cancer Res"},{"issue":"12","key":"11359_CR16","doi-asserted-by":"publisher","first-page":"T179","DOI":"10.1530\/erc-16-0422","volume":"23","author":"I Coutinho","year":"2016","unstructured":"Coutinho I, Day TK, Tilley WD, Selth LA (2016) Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer 23(12):T179\u2013T197. https:\/\/doi.org\/10.1530\/erc-16-0422","journal-title":"Endocr Relat Cancer"},{"key":"11359_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.115077","volume":"247","author":"Y Ji","year":"2023","unstructured":"Ji Y, Zhang R, Han X, Zhou J (2023) Targeting the N-terminal domain of the androgen receptor: the effective approach in therapy of CRPC. Eur J Med Chem 247:115077. https:\/\/doi.org\/10.1016\/j.ejmech.2022.115077","journal-title":"Eur J Med Chem"},{"key":"11359_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042124","author":"ML Mohler","year":"2021","unstructured":"Mohler ML, Sikdar A, Ponnusamy S, Hwang DJ, He Y, Miller DD et al (2021) A overview of Next-Generation Androgen Receptor-Targeted therapeutics in development for the treatment of Prostate Cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22042124","journal-title":"Int J Mol Sci"},{"key":"11359_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1451957","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Lan T (2024) N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review. Front Pharmacol 15:1451957. https:\/\/doi.org\/10.3389\/fphar.2024.1451957","journal-title":"Front Pharmacol"},{"issue":"1","key":"11359_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2295241","volume":"39","author":"X Qiao","year":"2024","unstructured":"Qiao X, Wu X, Chen S, Niu MM, Hua H, Zhang Y (2024) Discovery of novel and potent dual-targeting AXL\/HDAC2 inhibitors for colorectal cancer treatment via structure-based pharmacophore modelling, virtual screening, and molecular docking, molecular dynamics simulation studies, and biological evaluation. J Enzyme Inhib Med Chem 39(1):2295241. https:\/\/doi.org\/10.1080\/14756366.2023.2295241","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11359_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105740","volume":"220","author":"PP Parvatikar","year":"2023","unstructured":"Parvatikar PP, Patil S, Khaparkhuntikar K, Patil S, Singh PK, Sahana R et al (2023) Artificial intelligence: machine learning approach for screening large database and drug discovery. Antivir Res 220:105740. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105740","journal-title":"Antivir Res"},{"key":"11359_CR22","doi-asserted-by":"crossref","unstructured":"Chen T, Guestrin C (2016) XGBoost: A Scalable Tree Boosting System. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. p. 785\u201394.","DOI":"10.1145\/2939672.2939785"},{"issue":"D1","key":"11359_CR23","doi-asserted-by":"publisher","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","volume":"52","author":"B Zdrazil","year":"2024","unstructured":"Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S et al (2024) The ChEMBL database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res 52(D1):D1180\u2013D1192. https:\/\/doi.org\/10.1093\/nar\/gkad1004","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"11359_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.drudis.2014.10.012","volume":"20","author":"A Lavecchia","year":"2015","unstructured":"Lavecchia A (2015) Machine-learning approaches in drug discovery: methods and applications. Drug Discov Today 20(3):318\u2013331. https:\/\/doi.org\/10.1016\/j.drudis.2014.10.012","journal-title":"Drug Discov Today"},{"issue":"24","key":"11359_CR25","doi-asserted-by":"publisher","first-page":"9027","DOI":"10.1021\/acs.jcim.4c00863","volume":"64","author":"J Sieg","year":"2024","unstructured":"Sieg J, Feldmann CW, Hemmerich J, Stork C, Sandfort F, Eiden P et al (2024) Molpipeline: a Python package for processing molecules with RDKit in Scikit-learn. J Chem Inf Model 64(24):9027\u20139033. https:\/\/doi.org\/10.1021\/acs.jcim.4c00863","journal-title":"J Chem Inf Model"},{"issue":"2","key":"11359_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/php.12656","volume":"93","author":"DV Smirnova","year":"2017","unstructured":"Smirnova DV, Ugarova NN (2017) Firefly luciferase-based fusion proteins and their applications in bioanalysis. Photochem Photobiol 93(2):436\u2013447. https:\/\/doi.org\/10.1111\/php.12656","journal-title":"Photochem Photobiol"},{"issue":"2","key":"11359_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2144\/btn-2021-0017","volume":"71","author":"T Xu","year":"2021","unstructured":"Xu T, Gilliam M, Sayler G, Ripp S, Close D (2021) Screening for androgen agonists using autonomously bioluminescent HEK293 reporter cells. Biotechniques 71(2):403\u2013415. https:\/\/doi.org\/10.2144\/btn-2021-0017","journal-title":"Biotechniques"},{"issue":"4","key":"11359_CR28","first-page":"1809","volume":"43","author":"JS Horoszewicz","year":"1983","unstructured":"Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43(4):1809\u20131818","journal-title":"Cancer Res"},{"issue":"5","key":"11359_CR29","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NA Franken","year":"2006","unstructured":"Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protocols 1(5):2315\u20132319. https:\/\/doi.org\/10.1038\/nprot.2006.339","journal-title":"Nat Protocols"},{"issue":"11","key":"11359_CR30","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1248\/bpb.19.1518","volume":"19","author":"M Ishiyama","year":"1996","unstructured":"Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K (1996) A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19(11):1518\u20131520. https:\/\/doi.org\/10.1248\/bpb.19.1518","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"11359_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nprot.2007.30","volume":"2","author":"CC Liang","year":"2007","unstructured":"Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protocols 2(2):329\u2013333. https:\/\/doi.org\/10.1038\/nprot.2007.30","journal-title":"Nat. Protocols"},{"issue":"12","key":"11359_CR32","first-page":"3239","volume":"47","author":"A Albini","year":"1987","unstructured":"Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM et al (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47(12):3239\u20133245","journal-title":"Cancer Res"},{"issue":"9","key":"11359_CR33","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1073\/pnas.76.9.4350","volume":"76","author":"H Towbin","year":"1979","unstructured":"Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76(9):4350\u20134354. https:\/\/doi.org\/10.1073\/pnas.76.9.4350","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"11359_CR34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/29.4.6166661","volume":"29","author":"SM Hsu","year":"1981","unstructured":"Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem Off J Histochem Soci 29(4):577\u2013580. https:\/\/doi.org\/10.1177\/29.4.6166661","journal-title":"J Histochem Cytochem Off J Histochem Soci"},{"issue":"1","key":"11359_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1):33\u201339. https:\/\/doi.org\/10.1038\/nm972","journal-title":"Nat Med"},{"issue":"1","key":"11359_CR36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1210\/en.2005-1001","volume":"147","author":"JA Magee","year":"2006","unstructured":"Magee JA, Chang LW, Stormo GD, Milbrandt J (2006) Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 147(1):590\u2013598. https:\/\/doi.org\/10.1210\/en.2005-1001","journal-title":"Endocrinology"},{"issue":"38","key":"11359_CR37","doi-asserted-by":"publisher","first-page":"34583","DOI":"10.1021\/acsomega.3c03471","volume":"8","author":"NA Ghafoor","year":"2023","unstructured":"Ghafoor NA, Yildiz A (2023) Targeting MDM2-p53 axis through drug repurposing for cancer therapy: a multidisciplinary approach. ACS Omega 8(38):34583\u201334596. https:\/\/doi.org\/10.1021\/acsomega.3c03471","journal-title":"ACS Omega"},{"issue":"7","key":"11359_CR38","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/acs.jcim.1c00168","volume":"61","author":"R Al-Jarf","year":"2021","unstructured":"Al-Jarf R, de S\u00e1 AGC, Pires DEV, Ascher DB (2021) pdCSM-cancer: Using graph-based signatures to identify small molecules with anticancer properties. J Chem Inf Model 61(7):3314\u20133322. https:\/\/doi.org\/10.1021\/acs.jcim.1c00168","journal-title":"J Chem Inf Model"},{"issue":"1","key":"11359_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/v16010045","volume":"16","author":"S Gautam","year":"2023","unstructured":"Gautam S, Thakur A, Rajput A, Kumar M (2023) Anti-Dengue: a machine learning-assisted prediction of small molecule antivirals against dengue virus and implications in drug repurposing. Viruses 16(1):45. https:\/\/doi.org\/10.3390\/v16010045","journal-title":"Viruses"},{"key":"11359_CR40","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1016\/j.csbj.2022.06.060","volume":"20","author":"S Kamboj","year":"2022","unstructured":"Kamboj S, Rajput A, Rastogi A, Thakur A, Kumar M (2022) Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches. Comput Struct Biotechnol J 20:3422\u20133438. https:\/\/doi.org\/10.1016\/j.csbj.2022.06.060","journal-title":"Comput Struct Biotechnol J"},{"key":"11359_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1084327","volume":"14","author":"RH Pirzada","year":"2023","unstructured":"Pirzada RH, Ahmad B, Qayyum N, Choi S (2023) Modeling structure-activity relationships with machine learning to identify GSK3-targeted small molecules as potential COVID-19 therapeutics. Front Endocrinol 14:1084327. https:\/\/doi.org\/10.3389\/fendo.2023.1084327","journal-title":"Front Endocrinol"},{"issue":"21","key":"11359_CR42","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"issue":"2","key":"11359_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148. https:\/\/doi.org\/10.1056\/NEJMoa1209096","journal-title":"N Engl J Med"},{"issue":"13","key":"11359_CR44","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"issue":"2","key":"11359_CR45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/jco.2003.02.083","volume":"21","author":"SP Balk","year":"2003","unstructured":"Balk SP, Ko YJ, Bubley GJ (2003) Biology of prostate-specific antigen. J Clin Oncol 21(2):383\u2013391. https:\/\/doi.org\/10.1200\/jco.2003.02.083","journal-title":"J Clin Oncol"},{"key":"11359_CR46","doi-asserted-by":"publisher","DOI":"10.1172\/jci178604","author":"X Zhu","year":"2024","unstructured":"Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T et al (2024) Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. J Clin Invest. https:\/\/doi.org\/10.1172\/jci178604","journal-title":"J Clin Invest"},{"key":"11359_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.07.012","author":"P Rajwa","year":"2024","unstructured":"Rajwa P, Zapa\u0142a P, Merseburger AS (2024) Targeting androgen receptor alterations in metastatic prostate cancer. Euro Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2024.07.012","journal-title":"Euro Urol Focus"},{"issue":"21","key":"11359_CR48","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1158\/0008-5472.Can-24-0440","volume":"84","author":"S Ning","year":"2024","unstructured":"Ning S, Armstrong CM, Xing E, Leslie AR, Gao RY, Sharifi M et al (2024) LX1 dual targets AR variants and AKR1C3 in advanced Prostate Cancer therapy. Cancer Res 84(21):3617\u20133628. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-0440","journal-title":"Cancer Res"},{"issue":"5","key":"11359_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1230","volume":"13","author":"J Yu","year":"2023","unstructured":"Yu J, Shen T, Li Y, Hao T, Yang L, Li H et al (2023) Cytor drives prostate cancer progression via facilitating AR-V7 generation and its oncogenic signalling. Clin Transl Med 13(5):e1230. https:\/\/doi.org\/10.1002\/ctm2.1230","journal-title":"Clin Transl Med"},{"key":"11359_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032046","author":"E Tortorella","year":"2023","unstructured":"Tortorella E, Giantulli S, Sciarra A, Silvestri I (2023) AR and PI3K\/AKT in prostate cancer: a tale of two interconnected pathways. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24032046","journal-title":"Int J Mol Sci"},{"key":"11359_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216725","volume":"587","author":"H Chen","year":"2024","unstructured":"Chen H, Dong K, Ding J, Xia J, Qu F, Lan F et al (2024) Crispr genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression. Cancer Lett 587:216725. https:\/\/doi.org\/10.1016\/j.canlet.2024.216725","journal-title":"Cancer Lett"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11359-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11359-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11359-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:34:08Z","timestamp":1779536048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11359-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["11359"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11359-4","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}